POS0431 BASELINE VASCULAR ULTRASOUND OF PMR PATIENTS AT TIME OF DIAGNOSIS STRATIFIES RELAPSE RISK AT 6 MONTHSS. Cowley, David Kane, P. Harkins et al.|Annals of the Rheumatic Diseases|2024Cited by 2
POS0716 DIFFERENCES IN CLINICAL AND ULTRASOUND CHARACTERISTICS OF POLYMYALGIA RHEUMATICA PATIENTS WITH SUBCLINICAL GIANT CELL ARTERITIS COMPARED TO THOSE WITH CLINICAL GIANT CELL ARTERITISS. Cowley, David Kane, C. Kirby et al.|Annals of the Rheumatic Diseases|2023Cited by 1
OP0345 PROGNOSTIC VALUE OF QUANTIFYING VASCULAR INFLAMMATION THROUGH ULTRASOUND IN PATIENTS WITH GIANT CELL ARTERITIS: INTERIM ANALYSIS OF THE MAGiCUS STUDYJ. Molina Collada, C. Ponte, S. Monti et al.|Annals of the Rheumatic Diseases|2025Cited by 1
POS1426 OUTCOMES FROM A REAL-WORLD DEDICATED FAST-TRACK POLYMYALGIA RHEUMATICA CLINICSharon Cowley, Daniel Kane, P. Harkins et al.|Annals of the Rheumatic Diseases|2024Cited by 0
POS0518 Baseline levels of angiopoietin-1, IL-17A, and osteopontin may help differentiate subclinical GCA in PMR from pure PMRS. Cowley, David Kane, Tom Butler et al.|Annals of the Rheumatic Diseases|2025Cited by 0